Holen Sie sich die Stockscreener-App
1.52
3.40%
0.05
Handel nachbörslich:
1.53
0.01
+0.66%
Schlusskurs vom Vortag:
$1.47
Offen:
$1.48
24-Stunden-Volumen:
840.83K
Relative Volume:
1.01
Marktkapitalisierung:
$87.06M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-292.19M
KGV:
-0.3348
EPS:
-4.54
Netto-Cashflow:
$-208.41M
1W Leistung:
+25.62%
1M Leistung:
+21.60%
6M Leistung:
-56.57%
1J Leistung:
-86.28%
1-Tages-Spanne:
$1.45
$1.56
1-Wochen-Bereich:
$1.19
$1.60
52-Wochen-Spanne:
$1.01
$11.16
Zentalis Pharmaceuticals Inc Stock (ZNTL) Company Profile
Firmenname
Zentalis Pharmaceuticals Inc
Sektor
Branche
Telefon
(858) 263-4333
Adresse
10275 SCIENCE CENTER DRIVE, SAN DIEGO, NY
Vergleichen Sie ZNTL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ZNTL
Zentalis Pharmaceuticals Inc
|
1.52 | 87.06M | 0 | -292.19M | -208.41M | -4.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Zentalis Pharmaceuticals Inc Stock (ZNTL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-12 | Hochstufung | Wedbush | Underperform → Neutral |
| 2024-06-20 | Herabstufung | UBS | Buy → Neutral |
| 2024-06-18 | Herabstufung | Jefferies | Buy → Hold |
| 2024-06-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-18 | Herabstufung | Wedbush | Neutral → Underperform |
| 2024-06-18 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-11-08 | Herabstufung | Wedbush | Outperform → Neutral |
| 2023-11-07 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2022-07-12 | Eingeleitet | Cowen | Outperform |
| 2022-04-06 | Eingeleitet | Wells Fargo | Overweight |
| 2021-10-07 | Fortgesetzt | Jefferies | Buy |
| 2021-09-30 | Eingeleitet | Stifel | Buy |
| 2021-09-29 | Eingeleitet | Oppenheimer | Outperform |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-01-20 | Eingeleitet | Wedbush | Outperform |
| 2020-09-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-08-27 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-04-28 | Eingeleitet | Guggenheim | Buy |
| 2020-04-28 | Eingeleitet | Jefferies | Buy |
| 2020-04-28 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-04-28 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Zentalis Pharmaceuticals Inc Aktie (ZNTL) Neueste Nachrichten
Ameriprise Financial Inc. Purchases New Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Zentalis Pharmaceuticals Announces Azenosertib Fast Track Designation and Virtual Corporate Event to Present Updated Data from Azenosertib Clinical Studies - The Globe and Mail
ProShare Advisors LLC Lowers Holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Nuveen Asset Management LLC Has $1.94 Million Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Deutsche Bank AG Grows Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Two Sigma Investments LP Sells 291,801 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ZNTL Stock News - GuruFocus
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Zentalis Expands Cancer Research Team: 137K Share Options Granted to Key New Hires - Stock Titan
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Acquired by Millennium Management LLC - Defense World
Northern Trust Corp Raises Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
BNP Paribas Financial Markets Invests $534,000 in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Captrust Financial Advisors Buys New Stake in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Rating of “Hold” by Analysts - Defense World
Jane Street Group LLC Boosts Stock Holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Zentalis Pharmaceuticals at H.C. Wainwright BioConnect Conference - TipRanks
Balyasny Asset Management L.P. Has $175,000 Stock Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Wedbush Issues Optimistic Outlook for ZNTL Earnings - Defense World
Wedbush Reaffirms Neutral Rating for Zentalis Pharmaceuticals (NASDAQ:ZNTL) - Defense World
Zentalis Pharmaceuticals First Quarter 2025 Earnings: US$0.67 loss per share (vs US$0.14 profit in 1Q 2024) - Yahoo Finance
Zentalis Pharmaceuticals Reports Q1 2025 Financial Results - TipRanks
ZNTL Advances Azenosertib Development Amid Strategic Progress | - GuruFocus
Analyst Reiterates Neutral Rating for Zentalis Pharma (ZNTL) | Z - GuruFocus
ZNTL: Oppenheimer Adjusts Price Target Amid Regulatory Developme - GuruFocus
ZNTL: Oppenheimer Adjusts Price Target Amid Regulatory Developments | ZNTL Stock News - GuruFocus
Zentalis Pharma (ZNTL) Receives Buy Rating from HC Wainwright & Co. | ZNTL Stock News - GuruFocus
22,440 Shares in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Bought by Raymond James Financial Inc. - Defense World
Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress - GlobeNewswire
Zentalis Pharmaceuticals Inc (ZNTL) Q1 2025 Earnings: EPS Misses at -$0.67, Revenue Meets Estimate at $0.00 Million - GuruFocus
Zentalis Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Barclays PLC Grows Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
An analyst sees good growth prospects for Zentalis Pharmaceuticals Inc (ZNTL) - Sete News
Zentalis Pharmaceuticals Inc expected to post a loss of 64 cents a shareEarnings Preview - TradingView
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | ZNTL Stock News - GuruFocus
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Zentalis Expands Cancer Drug Development Team with Strategic New Hire Grant Worth $20,000 - Stock Titan
Was anything positive for Zentalis Pharmaceuticals Inc (ZNTL) stock last session? - uspostnews.com
Zentalis Pharmaceuticals Inc [ZNTL] Director makes an insider purchase of 21,000 shares worth 29373.0. - knoxdaily.com
Zentalis pharmaceuticals director Scott Myers acquires $29,372 in stock By Investing.com - Investing.com Canada
Zentalis pharmaceuticals director Scott Myers acquires $29,372 in stock - Investing.com Australia
Pleasing Signs As A Number Of Insiders Buy Zentalis Pharmaceuticals Stock - Yahoo Finance
Ratios Revealed: Decoding Zentalis Pharmaceuticals Inc (ZNTL)’s Financial Health - DWinneX
Zentalis shares insights on cancer research at AACR - Investing.com Australia
Zentalis (ZNTL) Advances with Phase 2 Trial in Ovarian Cancer | - GuruFocus
Zentalis shares insights on cancer research at AACR By Investing.com - Investing.com Canada
Zentalis Pharmaceuticals Doses 1st Patient in Part 2 of Ovarian Cancer Clinical Trial - marketscreener.com
Zentalis Doses First Patient In Phase 2 DENALI Trial Of Azenosertib In Cyclin E1+ PROC - Nasdaq
Zentalis Pharmaceuticals Announces First Patient Dosed in - GlobeNewswire
Breakthrough: New Cancer Drug Achieves 35% Response Rate in Hard-to-Treat Ovarian Cancer Patients - Stock Titan
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Purchased by Geode Capital Management LLC - Defense World
Finanzdaten der Zentalis Pharmaceuticals Inc-Aktie (ZNTL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Zentalis Pharmaceuticals Inc-Aktie (ZNTL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Bruns Ingmar | Chief Medical Officer |
Feb 06 '25 |
Buy |
2.28 |
20,000 |
45,656 |
36,629 |
1.21%
1.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):